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Background: Epigenetic adjustments of the chromatin architecture through histone modifications are reactive to
the environment and can establish chromatin states which are permissive or repressive to gene expression.
Epigenetic regulation of gene expression is cell specific and therefore, it is important to understand its contribution
to individual cellular responses in tissues like the airway epithelium which forms the mucosal barrier to the inhaled
environment within the lung. The airway epithelium of asthmatics is abnormal with dysregulation of genes such as
epidermal growth factor receptor (EGFR), the ΔN isoform of the transcription factor p63 (ΔNp63), and signal
transducer and activator of transcription 6 (STAT6), integral to differentiation, proliferation, and inflammation. It is
important to establish in diseases like asthma how histone modifications affect tissue responses such as
proliferation and differentiation.
Objectives: To characterize the global histone acetylation and methylation status in the epithelium of asthmatic
compared to healthy subjects and to identify the impact of these variations on genes involved in epithelial functions.
Methods: Whole lungs were obtained from healthy and asthmatic subjects (n = 6) from which airway epithelial cells
(AECs) were isolated and airway sections were taken for analysis of histone lysine acetylation and methylation by
immunohistochemistry. AECs were subjected to chromatin immunoprecipitation (ChIP) using anti-H3K18ac and
anti-H3K4me2 antibodies followed by RT-PCR targeting ΔNp63, EGFR, and STAT6. AECs were also treated with TSA
and changes in ΔNp63, EGFR, and STAT6 expression were determined.
Results: We identified an increase in the acetylation of lysine 18 on histone 3 (H3K18ac) and trimethylation of
lysine 9 on histone 3 (H3K9me3) in the airway epithelium of asthmatic compared to healthy subjects. We found
increased association of H3K18ac around the transcription start site of ΔNp63, EGFR, and STAT6 in AECs of
asthmatics. However, we were unable to modify the expression of these genes with the use of the HDAC
inhibitor TSA in healthy subjects.
Discussion: The airway epithelium from asthmatic subjects displays increased acetylation of H3K18 and
association of this mark around the transcription start site of ΔNp63, EGFR, and STAT6. These findings suggest a
complex interaction between histone modifications and gene regulation in asthma.* Correspondence: Tillie.Hackett@hli.ubc.ca
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The sequence of the human genome is essentially the
same in all cells of the body within a specific individual,
yet the epigenome differs from tissue to tissue [1]. The
DNA of each cell is packaged into nucleosomes where
146 base pairs of DNA wrap around an octamer of his-
tone proteins which contains two H2A, H2B, H3, and
H4 core histones [2]. An important mechanism for alter-
ing the chromatin structure to regulate gene expression
is the covalent modification of the amino acid residues
of core histone N-terminal tails [3, 4]. The acetylation of
lysine residues on histone tails, mediated by histone
acetyltransferases (HATs), has been positively associated
with gene transcription [3, 5]. Whereas histone deacety-
lases (HDACs) remove the acetyl mark from histone tails
resulting in a repressive chromatin state [3]. In contrast
to acetylation, methylation of histone tails can be both
activating and suppressive of gene expression depending
on the particular residue [3]. Methyl groups are added
to lysine or arginine residues by histone methyltransfer-
ases (HMTs) and removed by histone demethylases
(HDMs) [3, 5].
The role of epigenetics in the pathogenesis of asthma
remains unclear with evidence of both altered HAT and
HDAC activity and expression in the airways of asth-
matics [6–9]. In bronchial biopsies from asthmatic sub-
jects, HAT activity was shown to be elevated and HDAC
activity reduced [6, 7]. Although research investigating
the exact HDACs involved in asthma is inconsistent,
expression of certain inflammatory genes has been asso-
ciated with acetylation of histone lysine residues in an
epithelial cell line [10]. Further, histone methylation is a
key regulator of many genes involved in chronic inflam-
mation and epithelial mesenchymal transition [11–14]
and as such may also play a role in the regulation of
epithelial genes in asthma.
Abnormal expression of genes involved in repair and
inflammation has been reported in the epithelium of
asthmatic patients. The expression of epidermal growth
factor receptor (EGFR), important for migration, prolif-
eration, and differentiation, all integral components of
the repair process, is elevated in the epithelium of
childhood-onset and adult asthmatics [15–18]. Further,
the expression of EGFR is increased in both damaged
and intact regions of the airway epithelium of asthmatic
subjects [15, 16]. This overexpression of EGFR indi-
cates either that there is an unresolved repair process
or that the epithelium is locked in a repair phenotype
[15] contributing to the inflammatory and remodeling
processes. Furthermore, there is an increase in the number
of basal cells expressing the transcription factor p63 in
the asthmatic epithelium [19]. In particular, the ΔNp63
isoform is heavily expressed in the epithelium compared
to the larger TAp63 isoform [20]. ΔNp63 is essential fordifferentiation, adhesion, and proliferation [21, 22], and
thus, much like EGFR, is an important factor in epithe-
lial repair [20, 23]. The increased number of cells ex-
pressing p63 in the asthmatic epithelium may signify an
inappropriate differentiation program in asthma, which
would directly affect epithelial homeostasis and repair
[20]. Another transcription factor, signal transducer and
activator of transcription 6 (STAT6), is also overex-
pressed in the epithelium of severe asthmatics [24, 25].
In the epithelium, signaling through STAT6 activates
the chemokines CCL11 and CCL5 [26, 27], resulting in
the recruitment of eosinophils, basophils, T cells, and
leukocytes to the epithelium. This upregulation of STAT6
is believed to contribute to the chronic inflammation seen
in the airway mucosa of asthmatic patients. Together
these studies support the rationale that alterations in
the inflammatory and repair mechanisms of the airway
epithelium contribute to chronic inflammation and airway
remodeling in asthma.
Further, as the airway epithelium is the first point of
contact with inhaled environmental agents, it is well po-
sitioned for environmental factors to influence gene ex-
pression and ultimately susceptibility to disease through
epigenetic modifications. The impact of altered histone
modifications on the regulation of genes associated
with repair and inflammation in the epithelium of asth-
matic subjects is unclear. We therefore hypothesized
that epigenetic changes including histone acetylation
and methylation contribute to the abnormal expression
of EGFR, ΔNp63, and STAT6 in the epithelium of asth-
matic subjects and thus influence the disease pathogen-
esis. In this study we observed epigenetic differences in
the epithelium of asthmatic as compared to healthy
subjects. Specifically, we identified an increase in global
H3K18ac and H3K9me3 in the airway epithelium of
asthmatic subjects. We then found gene-specific alter-
ations to the histone acetylation status of of ΔNp63,
EGFR, and STAT6 in asthmatic airway epithelial cells,
however, attempting to modulate the expression of




Airway sections and AECs were obtained from non-
transplantable human donor lungs from the International
Institute for the Advancement of Medicine (Edison, NJ,
USA). The study was approved by the Providence Research
Ethics committee, University of British Columbia. AECs
from asthmatic and healthy subjects were isolated by pro-
tease digestion as previously described [28, 29]. Briefly, air-
ways were blunt-dissected and cut into 2-4 cm sections.
Segments were washed in PBS and placed in Bronchial
Epithelial Basal Media (BEBM; Lonza, Basel, Switzerland)
Table 2 Donor demographics for chromatin
immunoprecipitation and immunoblot
Phenotype n Average age° (range) Sex (M/F)
Asthma 5 18.2 (11-25) 3/2
Healthy 5 16.4 (11-20) 3/2
M male, F female
°There were no significant differences between age for disease groups;
unpaired two-tailed t-test p = 0.59
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washed in BEBM to aid cell dissociation and the harvested
cell suspension was passed through a 70 μm nylon mesh.
Pronase was neutralized after which the cell suspension
was collected and resuspended in BEGM containing an
antibiotic and antimycotic (Gibco). Cells were grown in
6-well plates in culture at 37 °C in 95 % air and 5 %
CO2 and used at passage 2 for all experiments. Donor
demographics for samples used for immunohistochem-
istry, chromatin immunoprecipitation, and immunoblot
are listed in Tables 1 and 2.
The human bronchial epithelial 16HBE14o- cell line
was kindly provided by the Gruenert laboratory [30] and
maintained in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) containing 10 % Fetal Bovine Serum
(FBS; Gibco) and an antibiotic and antimycotic (Gibco).
Cells were grown in 6-well plates in a 37 °C humidified
environment (95 % air/5 % CO2) and used at passage 4.
Immunohistochemical staining and image analysis of
airway sections
Formalin fixed, paraffin embedded airway tissue sec-
tions were used for immunohistochemical staining of
histone modifications. Briefly, 5 μm sections of airway
tissue were deparaffinized in xylene and then rehy-
drated with graded ethanol and processed for antigen
retrieval. Primary antibodies listed in Additional file 1:
Table S1 were diluted in the appropriate blocking
serum (goat or horse) and incubated overnight at 4 °C.
Sections were then incubated with a biotinylated goat
anti-rabbit or horse anti-mouse secondary antibody
(1:100, Vector Laboratories, Burlingame, CA, USA) for
60 min at room temperature. Signal was amplified
with the addition of Streptavidin-HRP (Dako) and the
chromogen 3,3-diaminobenzidine (Dako) was added for
visualization of antigen staining and counterstained
with Harris Hematoxylin Solution (Sigma, Oakville,
ON, Canada). Slides were dehydrated with graded
ethanol then coverslipped with Cytoseal 60 mounting
medium (Richard-Allan Scientific, Kalamazoo, MI,
USA). Tris-buffered saline was used for all washes
and dilutions.
Five images were obtained from each donor airway
using the Nikon Eclipse 700 (Nikon Instruments, Melville,
NY, USA), a 60x objective, and SPOT Advanced software
(Diagnostic Instruments, Sterling Heights, MI, USA). ToTable 1 Donor demographics for immunohistochemistry
Phenotype n Average age° (range) Sex (M/F)
Asthma 6 16 (8-26) 3/3
Healthy 6 17.3 (4-24) 4/2
M male, F female
°There were no significant differences between age for disease groups;
unpaired two-tailed t-test p = 0.77quantify staining, color segmentation and point counting
of nuclei were performed with ImagePro Plus software
(Media Cybernetics, Rockville, MD, USA). For color
segmentation, the same unit area was taken then the epi-
thelium was traced manually for each image. Colors indi-
cating positive staining were set at a threshold and a
measurement of this area was obtained followed by a
measurement of the total traced area of epithelium. These
values were used to calculate % positive area of airway
epithelium (area of positive stain/total epithelial area) as
previously described [31, 32]. For point counting, all
nuclei with positive staining were initially manually tagged
with a marker followed by a second marker to identify all
unstained nuclei. These values were then used to calculate
% positive nuclei (total positive nuclei/total nuclei *100)
for each image.Chromatin immunoprecipitation
AECs were grown in culture to 80 % confluence before
extraction of samples for chromatin immunoprecipita-
tion (ChIP) experiments. ChIP was performed using the
EpiTect ChIP Kit (Qiagen) according to the manufac-
turer’s protocol. Chromatin was sheared using a Sonic
Dismembrator Model 100 (Fisher Scientific) cycled at
30 s on, and 30 s off, for a total of 25 min. Sheared
chromatin was immunoprecipitated with 2 μg of either
H3K18ac (ab1191, Abcam), H3K4me2 (GAH-3203,
Qiagen) or IgG (Qiagen) antibody. DNA, including in-
put fraction, was purified using spin columns before
undergoing PCR.Real time polymerase chain reaction
Purified ChIP DNA was analyzed by quantitative real
time PCR for enrichment of target genes. RT2 SYBR
Green qPCR Master Mix (330520, Qiagen), 10 μM
primers, and ddH20 were mixed with immunoprecipi-
tated or input DNA and analyzed in triplicate by the
ViiA7 (Life Technologies). Primers used are listed in
Additional file 2: Table S2 and were designed to target
loci both upstream (I) and downstream (II) of the tran-
scription start site (TSS) except ΔNp63 where a suitable
downstream primer set could not be identified. In this
case, two loci upstream of the ΔNp63 TSS were chosen
Stefanowicz et al. Respiratory Research  (2015) 16:95 Page 4 of 13instead. Cycle threshold (Ct) values were recorded and
used to calculate % Input for each sample. Samples for
which the threshold cycle exceeded 35 were omitted
from analysis as these were considered unreliable
readings.
As per manufacturer’s protocol, confirmation of im-
munoprecipitation specificity was demonstrated by ana-
lyzing % Input at genes known to be expressed (positive
locus) and repressed (negative locus). Both H3K18ac
and H3K4me2 had high % Input at the glyceraldehyde-
3-phosphate dehydrogenase locus (GAPDH, transcrip-
tionally active euchromatin), and low % Input at the
spermidine/spermine N1-acetyltransferase family member
2 (SAT2, heterochromatin) and myogenic differentiation 1
loci (MYOD1, transcriptionally inactive euchromatin) in-
dicating antibody specificity (Additional file 3: Figure S1).
Trichostatin A treatment
AECs and 16HBE14o- cells were grown in 6-well plates to
80 % confluence. 16HBE14o- cells were treated for 24 h
with control media or the HDAC inhibitor Trichostatin A
(TSA, T8552, Sigma) at the following concentrations: 10,
100, 500, and 1000 ng/μl whereas AECs were treated with
control media or TSA at 100 ng/μl.SDS-PAGE and immunoblot
Depending on the molecular weight of each protein of
interest, a 10-18 % SDS-polyacrylamine gel was used to
ensure proper separation of proteins during electro-
phoresis. Following incubation with the specific primary
antibody (see Additional file 4: Table S3) overnight, mem-
branes were incubated for 2 h with either goat anti-mouse
IR-800 (Vector Laboratories) or goat anti-rabbit Alexa
680 (Invitrogen) secondary antibodies (1:2500 dilution).
Imaging of the labeled membrane was performed on the
LI-COR Odyssey system and Odyssey software 1.1 was
used to perform densitometry (LI-COR Biotechnology,
Lincoln, NE, USA).
Data for H3K18ac were normalized to total H3 and
presented as fold change over untreated control. Data
for ΔNp63 and STAT6 were normalized to β-tubulin
whereas EGFR was normalized to HSP-90 to maintain
resolution of the gel at a high molecular weight. All data
are presented as fold change over untreated control.Statistics
A two-tailed unpaired t-test was performed to determine
differences between asthmatic and healthy subjects for
all experiments except for the TSA dose response data,
for which a one-way ANOVA and a post hoc Dunnett’s
multiple comparison test was performed. A p-value of
less than 0.05 was deemed significant.Results
Increased acetylation of lysine 18 on histone 3 in
asthmatic airway epithelium
To determine if there were differences in global histone
acetylation between healthy and asthmatic epithelial tis-
sue, we compared histone acetylation of 6 lysine residues
on histones 3 and 4 (Fig. 1a-l). We identified a signifi-
cant increase in % positive area of airway epithelium for
acetylation of lysine 18 on histone 3 (H3K18ac) in asth-
matic compared to healthy subjects (p = 0.02, Fig. 1m).
However, when we counted the number of positive nu-
clei for H3K18ac, we found no difference between asth-
matic and healthy epithelium (Fig. 1n). This suggests
that more histones are acetylated at this particular resi-
due in each positively stained cell within the epithelium
from asthmatic subjects, which may affect the transcrip-
tional activity of more genes as compared to healthy
subjects. For the other acetylation marks, H3K14ac,
H3K27ac, H4K8ac, H4K12ac, and H4K16ac, we found
no difference in the % positive area or % positive nuclei
in epithelium from asthmatic compared to healthy
subjects (Additional file 5: Figure S2).
Increased histone 3 lysine 9 trimethylation (H3K9me3) in
asthmatic airway epithelium
As histone methylation has well defined roles in regulat-
ing many genes, we next investigated whether global his-
tone methylation differed between healthy and asthmatic
epithelium. We found no difference in global histone
methylation of the activating marks H3K4me2/me3, the
silencing mark H3K27me3, nor the differentiation asso-
ciated mark H3K36me3 (Fig. 2a-d,g-j, and Additional
file 6: Figure S2A, C, E, and G). Additionally, we did not
identify any differences in positively stained nuclei for
these methylated histone lysine residues (Additional
file 6: Figure S2B, D, F, and H). However, we did find a
significant increase in the amount of staining in the
airway epithelium for histone 3 lysine 9 trimethylation
(H3K9me3) in asthmatic compared to healthy subjects
(p = 0.015, Fig. 2e,f,k). This was mirrored by an increase
in the number of nuclei positive for H3K9me3 in the
epithelium from asthmatic subjects (p = 0.001, Fig. 2l).
As we observed an increase in the % positive area and %
positive nuclei of H3K9me3 in the epithelium of asth-
matics, this could reflect that there are increased num-
bers of cells containing this repressive histone mark and
not necessarily more of the H3K9me3 modification in
each cell.
Gene specific analysis of H3K18ac and H3K4me2 in
asthmatic airway epithelial cells
Although our staining analysis was restricted to the
airway epithelium our findings could also represent
changes in histone modifications within dendritic and
Fig. 1 Acetylation of histone lysine residues in asthmatic and healthy airways. Airway sections from asthmatic and healthy patients were formalin
fixed, embedded in paraffin and then sectioned for immunohistochemical analysis. Sections were stained for acetylation of H3K14ac (a, b),
H3K18ac (c, d), H3K27ac (e, f), H4K8ac (g, h), H4K12ac (i, j) or H4K16ac (k, l). Scale bar is equal to 50 μm. The expression of and the % of positive
nuclei stained for H3K18ac within the epithelium was quantified for both healthy (H, white bar) and asthmatic (A, blue bar) subjects (m, n). Data
are expressed as % of positive area of airway epithelium ± SEM (n = 6) and % positive nuclei ± SEM (n = 6). A two-tailed unpaired t-test was
performed, *indicates p < 0.05
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Fig. 2 Methylation of histone lysine residues in asthmatic and healthy airways. Airway sections from asthmatic and healthy patients were formalin
fixed, paraffin embedded and then sectioned for immunohistochemical analysis. Sections were stained for methylation of H3K4me2 (a, b),
H3K4me3 (c, d), H3K9me3 (e, f), H3K27me3 (g, h), and H3K36me3 (i, j). Scale bar is equal to 50 μm. The expression of and the % of positive nuclei
stained for H3K9me3 within the epithelium was quantified for both healthy (H, white bar) and asthmatic (A, blue bar) subjects (k, l). Data are
expressed as % of positive area of airway epithelium ± SEM (n = 6) and % positive nuclei ± SEM (n = 6). A two-tailed unpaired t-test was performed,
*indicates p < 0.05, **indicates p < 0.01
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lium and thus performing gene-specific experiments on
epithelial cell cultures was necessary. We focused on
H3K18ac, which had more staining per cell, as a poten-
tial modulator of genes overexpressed in the epithelium
of asthmatics. Chromatin immunoprecipitation was pre-
formed to identify whether the activating mark H3K18ac
was enriched in regions surrounding the transcription
start site (TSS) of ΔNp63, EGFR, and STAT6 as it has
been shown that the acetylation of H3K18 is augmented
predominantly around the TSS of active genes and not
transcribed regions of genes [33]. As dysregulation of
acetylation of the H3K18ac residue has been identified in
other diseases to occur alongside H3K4me2 [34–38], we
also investigated this activating epigenetic modification to
determine if any changes were unique to H3K18ac orpossibly part of a larger epigenetic phenomenon involving
other histone modifications.
As shown in Fig. 3a, we determined the association of
H3K18ac at both the ΔNp63-I and ΔNp63-II loci. The %
Input of H3K18ac at the ΔNp63-I locus in AECs from asth-
matic donors was 8.21 % ± 1.54, whereas healthy donors
showed 4.22 % ± 0.75 (p = 0.05, Fig. 3b). For ΔNp63-II,
AECs derived from asthmatic subjects showed a % Input of
8.81 % ± 1.78 while healthy donors displayed 4.41 % ± 0.51
for H3K18ac (p = 0.04, Fig. 3c). However, we found no dif-
ference in binding of H3K4me2 at the ΔNp63-I or ΔNp63-
II sites in AECs from asthmatic subjects compared to
controls (Fig. 3b and c respectively).
Next, in Fig. 4 we investigated whether H3K18ac and
H3K4me2 were differentially present surrounding the
EGFR transcription start site (Fig. 4a) in AECs from
Fig. 3 Association of H3K18ac and H3K4me2 at the ΔNp63 locus. Chromatin immunoprecipitation for H3K18ac, H3K4me2, and IgG was
performed on AECs from asthmatic and healthy subjects. Primers located around the transcription start site (TSS) of ΔNp63 (a) were used for real
time PCR targeting the ΔNp63-I (b) and the ΔNp63-II (c) loci. The presence of each histone modification and negative control was quantified and
expressed as % Input at the target locus ± SEM (n = 5). A two-tailed unpaired t-test was performed to determine differences in % Input between
asthmatic and healthy AECs for each locus, * indicates p < 0.05
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in asthmatic derived AECs was 11.92 % ± 0.95 as com-
pared to 7.21 % ± 1.04 for healthy subjects at the EGFR-I
locus (p = 0.03) but not for H3K4me2 (Fig. 4b). In con-
trast, we found no difference in association of H3K18ac
or H3K4me2 between AECs from healthy or asthmatic
subjects downstream of the EGFR TSS (Fig. 4c).
Lastly in Fig. 5, we investigated the association of
H3K18ac and H3K4me2 at the STAT6 TSS (Fig. 5a). In
AECs from asthmatic subjects, the % Input of H3K4me2
was not different while the % Input of H3K18ac was
greater than healthy subjects at the STAT6-I locus
(18.76 % ± 0.73 versus 12.07 % ± 1.50, p = 0.004, Fig. 5b).
We found no significant difference in binding of
H3K18ac or H3K4me2 at the downstream STAT6-II
locus in a comparison of healthy and asthmatic derived
AECs (Fig. 5c).Modulation of ΔNp63, EGFR, and STAT6 with
Trichostatin A
As the limited HAT inhibitors available exhibit low cell per-
meability and potency, we chose to investigate the function-
ality of acetylated H3K18ac in healthy AECs using the
histone deacetylase inhibitor Trichostatin A (TSA). To
ensure optimization, we first used the epithelial cell line
16HBE14o- and found that treatment of cells with
100 ng/μl TSA for 24 h resulted in significantly more
H3K18 acetylation compared to baseline untreated cells
(Fig. 6a and b). We next treated AECs from healthy donors
with 100 ng/μl TSA for 24 h to determine if we could alter
the expression of ΔNp63, EGFR, and STAT6 through
changes in histone acetylation. Although there was an in-
crease in protein expression of the three target genes
ΔNp63, EGFR, and STAT6 in AECs induced by TSA, these
changes were not statistically significant (Fig. 6c and d).
Fig. 4 Association of H3K18ac and H3K4me2 at the EGFR locus. Chromatin immunoprecipitation for H3K18ac, H3K4me2, and IgG was performed
on AECs from asthmatic and healthy subjects. Primers located around the transcription start site (TSS) of EGFR (a) were used for real time PCR
targeting loci both (b) upstream (EGFR-I) and (c) downstream (EGFR-II) of the TSS. The presence of each histone modification and negative
control was quantified and expressed as % Input at the target locus ± SEM (n = 5). A two-tailed unpaired t-test was performed to determine
differences in % Input between asthmatic and healthy AECs for each locus, *indicates p < 0.05
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The goal of our study was to identify specific histone
modifications that may affect the expression of ΔNp63,
EGFR, and STAT6 which are known to be altered in
the epithelium of asthmatic subjects. From a panel of
11 histone modifications, we identified an increase in
H3K18ac and H3K9me3 within the airway epithelium
of asthmatic compared to healthy subjects. As acetyl-
ation of histone lysine residues is generally associated
with a permissive chromatin structure and gene expres-
sion, we directed our focus to H3K18 and found increased
association of acetylated H3K18 around the transcription
start site of ΔNp63, EGFR, and STAT6 in AECs derived
from asthmatics when compared to healthy subjects.
These data indicate that global changes in acetylated
H3K18 may have important implications for defective
epithelial repair in asthma.
Recently, Qian et al. identified the necessity of HDAC2
in the regulation of ΔNp63 expression [39]. This mech-
anism is thought to be dependent on the interaction
between HDAC2 and the DEC1 transcription factor,which regulates ΔNp63 expression and has implications
for growth suppression and cellular differentiation [39].
Although the authors did not clarify the exact epigenetic
mechanism in terms of histone acetylation, they did find
that treatment of mammary epithelial cell lines with
the HDAC inhibitor TSA resulted in the induction of
ΔNp63 [39]. We identified elevated association of
H3K18ac at two regions upstream of the ΔNp63 TSS
in AECs from asthmatic donors. ΔNp63 is the most
prevalent p63 isoform expressed in human AECs with
the ability to regulate multiple genes involved in epi-
thelial functions such as proliferation and differenti-
ation [20]. The finding of elevated histone acetylation
at the ΔNp63 TSS provides insight into the possible
mechanism of ΔNp63 gene regulation. As HAT activity
is known to be increased in asthmatic epithelium [6, 7],
it is possible that ΔNp63 may be a target of this epi-
genetic aberration.
For epigenetic regulation of EGFR expression, Chou
et al. discovered a complex interaction between the his-
tone deacetylase HDAC3, the histone acetyltransferase
Fig. 5 Association of H3K18ac and H3K4me2 at the STAT6 locus. Chromatin immunoprecipitation for H3K18ac, H3K4me2, and IgG was performed
on AECs from asthmatic and healthy subjects. Primers located around the transcription start site (TSS) of STAT6 (a) were used for real time PCR
targeting loci both (b) upstream (STAT6-I) and (c) downstream (STAT6-II) of the TSS. The presence of each histone modification and negative
control was quantified and expressed as % Input at the target locus ± SEM (n = 5). A two-tailed unpaired t-test was performed to determine
differences in % Input between asthmatic and healthy AECs for each locus, *indicates p < 0.05
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in human colon carcinoma cells, the authors showed
that deacetylation of SP1 by HDAC3 results in increased
binding of SP1 to the EGFR promoter [40]. The subse-
quent association of CBP with the SP1/HDAC3 complex
results in histone acetylation and EGFR expression [40].
Of interest, the authors also suggested that priming of
the EGFR gene was due to histone methylation, as they
found enrichment of H3K4me2 at the EGFR promoter
[40]. Another study in breast cancer epithelial cells
found that EGFR is repressed by binding of the TIEG1/
HDAC1 complex to SP1 sites on the EGFR promoter
resulting in suppression of histone acetylation [41]. Our
finding of increased association of acetylated H3K18
upstream of the EGFR TSS in AECs from asthmatics
indicates that histone acetylation may be an epigenetic
regulatory component of epithelial EGFR overexpres-
sion observed in asthma. Evidence of epigenetic regula-
tion of EGFR has significant implications in the setting
of asthma given its role in epithelial functions such asdifferentiation and proliferation and may provide a
novel therapeutic modality in this disease.
STAT6 may interact with histone acetyltransferases and
demethylases to facilitate transcriptional activation of
STAT6 target genes [42–44] but the mechanism by which
STAT6 itself is regulated by histone modification is not
understood. Within the epithelium, STAT6 is an integral
transcription factor in IL-13 mediated pathology and
eotaxin gene activation [27, 45, 46]. Although the import-
ance of STAT6 in the inflammatory process is recognized
and STAT6 levels are elevated in the asthmatic epithelium
[24], regulatory mechanisms controlling expression of this
gene have yet to be elucidated. We identified elevated
association of H3K18ac upstream of the STAT6 TSS in
AECs from asthmatic compared to healthy donors. As his-
tone acetylation is commonly associated with gene expres-
sion, our finding may provide an epigenetic mechanism
for the increase in STAT6 expression seen in asthma.
Although differential levels of histone modifications
may vary depending on specific disease pathology, there
Fig. 6 Modulation of H3K18ac, ΔNp63, EGFR, and STAT6 expression with TSA treatment. a and b: 16HBE14o- cells were treated with TSA at 0, 10,
100, 500, and 1000 ng/μl for 24 h. Protein was collected and SDS-PAGE immunoblot was performed to quantify H3K18ac and total H3. Data are
presented as fold change H3K18ac normalized to H3 ± SEM (n = 3). A one-way ANOVA and a post hoc Dunnett’s multiple comparison test was
performed. c and d: AECs from healthy subjects were treated with TSA (100 ng/μl) for 24 h. Protein was collected and SDS-PAGE immunoblot
was performed to quantify the change in ΔNp63, EGFR, and STAT6 protein between control and TSA treated samples. Data are presented as fold
change normalized to loading control (β-tubulin for ΔNp63 and STAT6, and hsp90 for EGFR) ± SEM (n = 5). A two-tailed paired t-test was
performed for control versus treatment for each gene. *indicates p < 0.05
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H3K18ac and H3K4me2 in cellular processes including
differentiation. Specifically, low global cellular levels of
these histone modifications have been identified in stud-
ies of prostate [36], pancreatic [37], kidney [38], and
lung cancer [38] as predictors of poor prognosis. How-
ever, studies investigating global histone modifications in
esophageal squamous cell carcinoma indicate that high
global levels of H3K18ac and H3K4me2 are associated
with tumor grade whereas low levels of H3K18ac are
correlated to a better prognosis [35]. As tumor grade
increases, carcinoma cells become more poorly differen-
tiated [47], thus it is possible that the genes affected by
H3K18ac and H3K4me2 in esophageal squamous cellcarcinoma may contribute to halting the cellular differenti-
ation program. Within our study, the % Input of H3K4me2
was not different between asthmatics and controls at the
three genes examined, however, H3K4me2 was enriched at
similar or higher amounts as H3K18ac at each site. This
may support the theory that H3K4me2 primes the region
for mechanisms, such as histone acetylation, which facili-
tate gene expression however further investigations are re-
quired to elucidate this interaction.
Due to the challenges with available HAT inhibitors and
their use in cell culture, including low cell-permeability,
low potency, and a lack of specificity [48], we focused on
HDAC inhibition to drive ΔNp63, EGFR, and STAT6 gene
expression. Since epithelial cells from healthy subjects
Stefanowicz et al. Respiratory Research  (2015) 16:95 Page 11 of 13displayed lower levels of H3K18ac at ΔNp63, EGFR, and
STAT6, we hypothesized that exposure to the potent
HDAC inhibitor TSA would increase the expression of
these genes. Although TSA was able to induce H3K18
hyperacetylation in the 16HBE14o- cell line suggesting it
was active, TSA exposure did not significantly increase the
levels of ΔNp63, EGFR, or STAT6 in healthy AECs. These
results could be due to the fact that TSA functions pri-
marily on class I and class II but not class III deacetylases
[49]. Recently, SIRT7 was identified as an H3K18ac spe-
cific class III histone deacetylase [50]. SIRT7 exerts its
effects on genes which contain the ELK4 transcription
factor binding site [50]. Interestingly, the ELK4 binding
site has been identified close to the TSS of the STAT6
gene [50] and thus it is possible that deacetylation of
H3K18 in at least one of the genes of interest is regulated
by SIRT7. Another factor is that protein samples were
collected 24 h post TSA treatment which may have been
adequate time to induce alterations in histone acetylation,
but not for the production of target proteins.
Numerous epigenetic mechanisms are now being pro-
posed as pharmaceutical targets for various disease
pathologies [51]. Such therapies that modify the epige-
nome are creating promising treatment options for
diseases such as cancer, Huntington’s, and amyotrophic
lateral sclerosis [52, 53]. In fact, the pan-HDAC inhibi-
tors Vorinostat and Romidepsin have already been
granted Food and Drug Administration approval for
treatment of cutaneous T cell lymphoma [54, 55]. In
terms of airway disease, the drug theophylline, which
exerts it effects by activating HDAC2, is used to treat
patients with corticosteroid resistant chronic obstruct-
ive pulmonary disease and has the potential to treat
corticosteroid insensitive asthmatics [56–58]. When
HDAC2 is allowed to function properly, it is recruited
to inflammatory gene promoters by glucocorticoid re-
ceptors resulting in histone deacetylation and gene si-
lencing [56, 57]. In this study we demonstrate increased
H3K18 acetylation in the asthmatic epithelium. While
the full clinical potential of epigenetic therapy has yet
to be realized, for many histone modifications such as
acetylation there are limited specific inhibitors. How-
ever, with a greater understanding of the role of epigenet-
ics in the pathology of asthma, future work can be guided
to develop specific epigenetic therapeutic options.
Although we show significant alterations in epithelial
gene specific acetylation of H3K18 in asthma, our study
does have limitations. Firstly, there is evidence that his-
tone acetylation of inflammatory genes is responsive to
corticosteroids [59], thus future studies stratifying the
levels of H3K18ac by steroid use will be imperative to
fully understand this epigenetic mechanism. In addition,
the effects of HDAC inhibitors (including TSA) on in-
flammatory gene expression has been documented innumerous epithelial cell types [60]. Altered expression of
important inflammatory genes in asthma pathogenesis
such as interleukins and matrix metalloproteinases has
been identified in response to TSA treatment [61–63].
As such, future work investigating the regulation of
inflammatory genes through modulation of histone
acetylation would be an exciting avenue to follow up.
Secondly, we had to use donor lungs to obtain a suffi-
cient quantity of primary AECs for the experiments
conducted in this study and therefore have a relatively
small sample size (n = 6 per group), thus further replica-
tion will be necessary. However, power calculations of
the global increase in H3K18ac in asthmatic subjects
show that this data is over 90 % powered to identify a
significant effect. Lastly, we have not looked at other epi-
genetic mechanisms, such as DNA methylation, which
may be important in the regulation of the genes exam-
ined in this study. Indeed, there is evidence of DNA
methylation regulating the expression of EGFR, ΔNp63,
and STAT6 in both human and animal studies [64–66].
However, previous work performed in our laboratory did
not identify differential DNA methylation of EGFR in
AECs from asthmatic, atopic or healthy subjects [67].
Conclusions
In summary, we have identified elevated levels of acety-
lated lysine 18 on histone 3 in the epithelium of asth-
matic as compared to healthy subjects. This does not
exclude differences in various histone modifications at
the gene-specific level, but it does provide a starting
point for a possible epigenetic target for overexpressed
genes in the airway epithelium of asthmatics. This is es-
pecially relevant as we identified elevated association of
H3K18ac at the TSS of three genes which have been dem-
onstrated to be dysregulated in the asthmatic epithelium,
specifically ΔNp63, EGFR, and STAT6. However, the
HDAC inhibitor TSA did not significantly alter the ex-
pression of these genes which may suggest a more com-
plex mechanism of epigenetic control of gene expression
in AECs. This study therefore highlights the need for de-
velopment of more specific therapeutic epigenetic modify-
ing agents to further understand the complexity of
epigenetic modulators in asthma.
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